UK-based biotechnology firm Tiziana Life Sciences has executed an agreement with STC Biologics for the manufacture of TZLS-501 for clinical studies in Covid-19 patients.
STC Biologics has completed construction of a single-use mammalian GMP manufacturing facility in Newton, MA, and has successfully conducted its first MCB and three GMP drug substance production runs.